Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry.
Michail VikelisEmmanouil V DermitzakisGeorgia XiromerisiouDimitrios RallisPanagiotis SoldatosPantelis LitsardopoulosDimitrios RikosHaralabos P KalofonosPublished in: Journal of clinical medicine (2023)
fremanezumab appears to be effective as a preventive treatment in difficult-to-treat CM patients with and without PCs while also being beneficial in reducing the severity of comorbid anxiety and/or depression.